Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.

Abstract excerpt

Small molecule kinase inhibitors of the epidermal growth factor receptor (EGFR) have recently been found to exhibit clinical efficacy in the setting of nonsmall cell lung cancers that harbor activating EGFR mutations. However, the remissions induced by these drugs (Iressa and Tarceva) are typically short-lived, presumably due to acquired drug resistance. We recently reported findings demonstrating that a distinct...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Catalysis
• Share to Drug Resistance, Neoplasm
• Share to Enzyme Inhibitors